Roche: positive two-year data for Susvimo

(CercleFinance.com) - Roche announces two-year results for the Pagoda and Pavilion Phase III studies, demonstrating sustained efficacy of Susvimo for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR), respectively.


This data, presented at the ASRS 2024 congress in Stockholm, demonstrate the potential of this rechargeable ocular implant as an alternative to ocular injections for treating these two main causes of vision loss in diabetic adults.

In addition, the Swiss healthcare group reports that the US FDA has accepted its application for a license for Susvimo in these two diseases, based on one-year data from the Pagoda and Pavilion studies.


Copyright (c) 2024 CercleFinance.com. All rights reserved.